Spruce Biosciences (SPRB) Receivables (2023)
Spruce Biosciences (SPRB) posted quarterly Receivables of $15.0 million for Q1 2023.
Spruce Biosciences (SPRB) Receivables (2023) Analysis & Trends
Spruce Biosciences (SPRB) has reported Receivables for 1 consecutive years, with $15.0 million the latest figure, recorded in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 86.55 Bn | 78.55 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 59.81 Bn | 54.67 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 31.87 Bn | 28.56 Bn | 992.69 Mn | 912.74 Mn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | 1.09 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 215.33 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | - |
| 10 | Spruce Biosciences | 123.98 Mn | 123.98 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 15.00 Mn |